Covid: AstraZeneca vaccine 79% effective with no increased blood clot risk – US trial

Study of over 32,000 people included review of risks of cerebral venous sinus thrombosis

1
737

VT: Before it’s over, the blood clot hoax out of Norway will have killed thousands.  Why?  Who is paying them?  Suggest it might be someone producing a competing vaccine?

The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval.

The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

The data will give credence to the British vaccine after results from earlier, separate late-stage studies raised questions about the robustness of the data.



It will also help allay safety concerns that have disrupted its use in the EU after a small number of reports of rare blood clots in people who had received the jab.

After briefly halting its use, many European countries have resumed using the product in their inoculation programmes after a regional regulator said it was safe, and several country leaders have been receiving the jab to boost confidence.

AstraZeneca said an independent safety committee conducted a specific review of the blood clots in the US trial, as well as cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, with the help of an independent neurologist.

The London-listed company said the panel found “no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial”.

The partners will prepare the data to apply for approval from the US Food and Drug Administration (FDA), University of Oxford professor Sarah Gilbert told BBC radio. The preparation will take a few weeks, she added.  read more…

https://www.theguardian.com/society/2021/mar/22/astrazeneca-covid-vaccine-79-effective-with-no-increased-blood-clot-risk-us-trial

ATTENTION READERS

We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.

1 COMMENT

  1. You are quoting “The Guardian” newspaper, Holy Moly Batman !!!!!!!!!!!!! That’s like quoting the BBC and stating its “The Gods honest truth Guv’nor”……………………hardly. Sorry Carol, to much double speak to be a plausible article. We here in Austria have kicked it into touch, for the mo’ at least. The rest of the bunch of so-called vaccines, are nothing less than nano-technology transportation methods, care of Gates, Schwab, Soros and Co. Sputnik V or Hydroxychloroquinine is the way to go, if you MUST be vaxxed or treated.

Comments are closed.